Pharmaceuticals

Atherosclerosis Drugs Market Outlook Highlighting Demand Growth from 2026–2030

March 18, 2026April 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Atherosclerosis Drugs Market During 2026–2030?

The atherosclerosis drugs market size has shown consistent growth recently. It is projected to expand from $50.91 billion in 2025 to $52.45 billion in 2026, achieving a compound annual growth rate (CAGR) of 3.0%. This historical growth can be attributed to factors such as the increasing prevalence of cardiovascular diseases, heightened awareness regarding heart health, the widespread adoption of statins and other cholesterol-lowering drugs, governmental initiatives focused on cardiovascular care, and the expansion of hospital and retail pharmacy infrastructure.

The atherosclerosis drugs market is projected to experience consistent expansion over the upcoming years. This market is anticipated to reach $61.19 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 3.9%. Factors driving this growth during the forecast period include the broadening application of precision medicine in cardiovascular care, the greater uptake of digital health monitoring instruments, the increasing need for combination therapies, an expanding elderly demographic, and advancements in new anti-atherosclerosis drug categories. Key trends anticipated for the forecast period encompass personalized atherosclerosis treatments, multi-drug formulations, assistance for minimally invasive procedures, proactive cardiovascular health management, and enhanced patient compliance coupled with digital oversight.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12621&type=smp

Which Economic Or Industry Drivers Are Impacting The Atherosclerosis Drugs Market?

The rising incidence of cardiovascular diseases is anticipated to fuel the expansion of the atherosclerosis drug market moving forward. Cardiovascular diseases include all conditions that affect the heart and blood vessels, whereas atherosclerosis is defined by the accumulation of fats, cholesterol, and other substances on a person’s artery walls. Atherosclerosis is characterized by the formation of plaque inside the arteries, leading to cardiovascular ailments like coronary heart disease and stroke. Atherosclerosis drugs are utilized to manage cardiovascular diseases by lowering the chance of complications and controlling underlying issues such as elevated cholesterol levels and blood clot formation. For instance, in January 2024, the American Heart Association, a US-based non-profit organization, reported that the age-adjusted death rate from cardiovascular disease climbed to 233.3 per 100,000 in 2024, representing an increase of 4.0% from 224.4 per 100,000 in 2023. Hence, the widespread occurrence of cardiovascular diseases will propel the atherosclerosis drug market.

How Are The Various Segments Of The Atherosclerosis Drugs Market Categorized?

The atherosclerosis drugs market covered in this report is segmented –

1) By Drug Class: Anti-Platelet Medications, Fibric Acid And Omega-3 Fatty Acid Derivatives, Angiotensin-Covering Enzyme (ACE) Inhibitors, Diuretics, Cholesterol Lowering Medication, Beta Blockers, Calcium Channel Blockers, Other Drug Classes

2) By Route Of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:

1) By Anti-Platelet Medications: Aspirin, Clopidogrel, Ticagrelor

2) By Fibric Acid And Omega-3 Fatty Acid Derivatives: Fenofibrate, Gemfibrozil, Omega-3 Fatty Acid Supplements

3) By Angiotensin-Covering Enzyme (ACE) Inhibitors: Lisinopril, Enalapril, Ramipril

4) By Diuretics: Thiazide Diuretics, Loop Diuretics, Potassium-Sparing Diuretics

5) By Cholesterol Lowering Medication: Statins, PCSK9 Inhibitors, Bile Acid Sequestrants

6) By Beta Blockers: Metoprolol, Atenolol, Carvedilol

7) By Calcium Channel Blockers: Amlodipine, Diltiazem, Verapamil

8) By Other Drug Classes: Anticoagulants, Vasodilators, Cholesterol Absorption Inhibitors

What Trends Are Affecting The Expansion Of The Atherosclerosis Drugs Market?

Major companies operating in the atherosclerosis drugs market are actively developing novel products, such as anti-inflammatory medications, aiming to boost their market profitability. Atherosclerosis anti-inflammatory drugs are defined as treatments specifically designed to lessen the inflammation associated with atherosclerosis, a condition where plaque accumulates in the arteries. For example, in June 2023, AGEPHA Pharma, a European manufacturer of medical products, introduced LODOCO. The U.S. FDA has granted approval to LODOCO (colchicine, 0.5 mg tablet) as the inaugural anti-inflammatory atheroprotective cardiovascular treatment. This drug has shown proven effectiveness in decreasing the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adults afflicted with atherosclerotic disease or those having multiple cardiovascular risk factors. LODOCO addresses residual inflammation, recognized as a crucial element in atherosclerotic cardiovascular disease (ASCVD). Approved for administration either alone or concurrently with cholesterol-lowering medications, this drug represents a notable advancement in the field of cardiovascular care.

Which Major Firms Influence Developments In The Atherosclerosis Drugs Market?

Major companies operating in the atherosclerosis drugs market are Johnson And Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Janssen Pharmaceuticals Inc., Novartis AG, Merck And Co. Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Regeneron Pharmaceuticals Inc., Lupin Limited, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Amarin Corporation plc, Esperion Therapeutics Inc., Kowa Pharmaceuticals America Inc.

Read the full atherosclerosis drugs market report here:

https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report

What Are The Top-Performing Regions Within The Atherosclerosis Drugs Market?

North America was the largest region in the atherosclerosis drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atherosclerosis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Atherosclerosis Drugs Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12621&type=smp

Browse Through More Reports Similar to the Global Atherosclerosis Drugs Market 2026, By The Business Research Company

Atherosclerosis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report

Cardiovascular Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report

Atorvastatin Market Report 2026

https://www.thebusinessresearchcompany.com/report/atorvastatin-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795